Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID versus TRANEXAMIC ACID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID versus TRANEXAMIC ACID.
AMINOCAPROIC ACID vs TRANEXAMIC ACID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by binding to plasminogen and blocking its conversion to plasmin.
Competitive inhibitor of plasminogen activation, blocking the binding of plasminogen to fibrin, thereby preventing fibrinolysis and stabilizing clots.
Loading dose: 4-5 g intravenously (IV) over 1 hour, followed by continuous IV infusion of 1 g/hour for 8 hours or until bleeding controlled. Oral: 1 g every hour for 8 hours, then 1 g every 2 hours for 8 additional hours.
1 g intravenously every 8 hours for prophylaxis of bleeding in cardiac surgery; for heavy menstrual bleeding: 1.3 g orally three times daily for up to 5 days during menstruation.
None Documented
None Documented
Clinical Note
moderateTranexamic acid + Estrone sulfate
"Tranexamic acid may increase the thrombogenic activities of Estrone sulfate."
Clinical Note
moderateTranexamic acid + Estramustine
"Tranexamic acid may increase the thrombogenic activities of Estramustine."
Clinical Note
moderateTranexamic acid + Tretinoin
"Tranexamic acid may increase the thrombogenic activities of Tretinoin."
Clinical Note
moderateAminocaproic acid + Tretinoin
Terminal elimination half-life is approximately 2 hours (range 1-3 hours) in patients with normal renal function. Prolonged in renal impairment (up to 20 hours in anuria).
Terminal elimination half-life approximately 2-11 hours (mean 2 hours in healthy adults; prolonged to 7-15 hours in renal impairment). Clinical context: dosing interval adjustment required in renal insufficiency.
Primarily renal (80-90% unchanged). A small fraction (<5%) is excreted as metabolites. No significant biliary/fecal elimination.
Primarily renal excretion as unchanged drug (95% within 24 hours) via glomerular filtration; minimal biliary/fecal elimination (<5%).
Category C
Category A/B
Antifibrinolytic
Antifibrinolytic
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."